دورية أكاديمية
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling
| العنوان: | Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling |
|---|---|
| المؤلفون: | Gao, Shan, Bajrami, Ilirjana, Verrill, Clare, Kigozi, Asha, Ouaret, Djamila, Aleksic, Tamara, Asher, Ruth, Han, Cheng, Allen, Paul, Bailey, Deborah, Feller, Stephan, Kashima, Takeshi, Athanasou, Nicholas, Blay, Jean-Yves, Schmitz, Sandra, Machiels, Jean-Pascal, Upile, Nav, Jones, Terry M, Thalmann, George, Ashraf, Shazad Q, Wilding, Jennifer L, Bodmer, Walter F, Middleton, Mark R, Ashworth, Alan, Lord, Christopher J, Macaulay, Valentine M |
| المساهمون: | UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service d'oto-rhino-laryngologie |
| المصدر: | Cancer Research, Vol. 74, no.20, p. 5866-5877 (2014) |
| بيانات النشر: | American Association for Cancer Research |
| سنة النشر: | 2014 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Adaptor Proteins, Signal Transducing, Inhibitory Concentration 50, Insulin-Like Growth Factor I, Isoxazoles, MAP Kinase Signaling System, Male, Mice, Phosphoproteins, Pyrimidines, Receptor, IGF Type 1, Wnt Proteins, Animals, Xenograft Model Antitumor Assays, ras Proteins, Antineoplastic Agents, Carcinoma, Squamous Cell, Cell Line, Tumor, Drug Resistance, Neoplasm, Gene Expression, Head and Neck Neoplasms, Humans |
| الوصف: | Drugs that inhibit insulin-like growth factor 1 (IGFI) receptor IGFIR were encouraging in early trials, but predictive biomarkers were lacking and the drugs provided insufficient benefit in unselected patients. In this study, we used genetic screening and downstream validation to identify the WNT pathway element DVL3 as a mediator of resistance to IGFIR inhibition. Sensitivity to IGFIR inhibition was enhanced specifically in vitro and in vivo by genetic or pharmacologic blockade of DVL3. In breast and prostate cancer cells, sensitization tracked with enhanced MEK-ERK activation and relied upon MEK activity and DVL3 expression. Mechanistic investigations showed that DVL3 is present in an adaptor complex that links IGFIR to RAS, which includes Shc, growth factor receptor-bound-2 (Grb2), son-of-sevenless (SOS), and the tumor suppressor DAB2. Dual DVL and DAB2 blockade synergized in activating ERKs and sensitizing cells to IGFIR inhibition, suggesting a nonredundant role for DVL3 in the Shc-Grb2-SOS complex. Clinically, tumors that responded to IGFIR inhibition contained relatively lower levels of DVL3 protein than resistant tumors, and DVL3 levels in tumors correlated inversely with progression-free survival in patients treated with IGFIR antibodies. Because IGFIR does not contain activating mutations analogous to EGFR variants associated with response to EGFR inhibitors, we suggest that IGF signaling achieves an equivalent integration at the postreceptor level through adaptor protein complexes, influencing cellular dependence on the IGF axis and identifying a patient population with potential to benefit from IGFIR inhibition. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | Ndonga |
| تدمد: | 0008-5472 1538-7445 |
| العلاقة: | boreal:157040; http://hdl.handle.net/2078.1/157040Test; info:pmid/25168481; urn:ISSN:0008-5472; urn:EISSN:1538-7445 |
| DOI: | 10.1158/0008-5472.CAN-14-0806 |
| الإتاحة: | https://doi.org/10.1158/0008-5472.CAN-14-0806Test http://hdl.handle.net/2078.1/157040Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.7CBFE460 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 00085472 15387445 |
|---|---|
| DOI: | 10.1158/0008-5472.CAN-14-0806 |